CHOICES = Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia

Study title

CHOICES = Imatinib Mesylate With or Without Hydroxychloroquine to Eliminate Malignant Stem Cells in Patients With Chronic Myeloid Leukemia [Europe]

Scientific title

A Randomized Phase II Trial of Imatinib (IM) Versus Hydroxychloroquine (HCQ) and IM for Patients With Chronic Myeloid Leukemia (CML) in Major Cytogenetic Response (MCyR) With Residual Disease Detectable by Quantitative Polymerase Chain Reaction (Q-PCR) (EudraCT 2009-014373-41, ClinicalTrials.gov NCT01227135)

Indication and most important inclusion criteria

Chronic myeloid leukemia (CML) in chronic phase (CP)
Potential participants should have received imatinib mesylate for at least 1 year, and received a stable dose for at least 6 months. They should have achieved at least major cytogenetic response (MCyR) and continue to be BCR/ABL-positive by quantitative polymerase chain reaction (Q-PCR).

Short description of intervention

This trial is conducted to analyze the benefits and side effects of giving imatinib mesylate with or without hydroxychloroquine in patients with chronic myeloid leukemia. Patients will receive treatment for up to 12 months during the study period and possibly for up to 12 months during the follow-up period.

Type of study

Treatment optimization trial

Current status

No longer recruiting

Study sponsor

NHS Greater Glasgow and Clyde
Funded by Medical Research Council and supported by Cancer Research UK Trials unit Glasgow

Scientific lead / contact

Lynn McMahon
University of Glasgow

Principal investigator

Holyoake, Prof. Dr. Tessa
Gartnavel General Hospital
Institut of Cancer Sciences

Additional information

Patient Information Sheet

Study description in the EU Clinical Trials Register which is hosted by the European Medicines Agency (EMA)

Short protocol in European LeukemiaNet

Study centers / principal investigators


United Kingdom


Glasgow
Gartnavel General Hospital
Institut of Cancer Sciences
Prof Dr Tessa Holyoake

Leeds
St James University Hospital Leeds
Dr Graeme Smith

Liverpool
Royal Liverpool University Hospital
Prof Richard E. Clark

London
Addenbrookes Hospital
Dr Brian Huntley

Imperial College London
Dr David Marin

Nottingham
Nottingham University Hospital
Dr Jenny Byrne


France

Lyon
Hospices Civils de Lyon
Dr Franck Nicolini


Germany


Uniklinik RWTH Aachen
Klinik für Onkologie, Hämatologie und SZT
Prof. Dr. med. Steffen Koschmieder

Universitätsklinik Hamburg-Eppendorf
PD Dr. med. Philippe Schafhausen

Eltrombopag for thrombocytopenia in CML

Study title

Eltrombopag for low platelet count associated with TKI in CML [USA]

Scientific title

Eltrombopag for the management of thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia (CML) and myelofibrosis (MF) (ClinicalTrials.gov NCT01428635)

Indication and most important inclusion criteria

This study includes patients 18 years and older diagnosed with CML in chronic phase. Patients must have been receiving an FDA-approved tyrosine kinase inhibitor (TKI) for at least 3 months.
Patients must have a decrease of platelets in the blood (known as "thrombocytopenia"), grade 3, that is recurrent (at least two episodes) or requiring dose reductions of the tyrosine kinase inhibitor.

Short description of intervention

Patients with CML receiving tyrosine kinase inhibitors who develop persistent or profound decrease of platelets ("thrombocytopenia") are offered eltrombopag together with continuation of their TKI. The goal of this study is to learn if eltrombopag can improve the platelet count in the blood.

Type of study

Other studies
In a single country

Current status

No longer recruiting patients

Study sponsor

MD Anderson Cancer Center

Scientific lead / contact

Jorge Cortes

Principal investigator

Gautam Borthakur

Additional information

Study description in the US register ClinicalTrials.gov, a service of the U. S. National Institutes of Health

Study centers / principal investigators

United States

MD Anderson Cancer Center
University of Texas
Houston, Texas

 

 

SPIRIT2 = Comparison of imatinib versus dasatinib in patients with newly-diagnosed chronic phase chronic myeloid leukaemia Scientific title

Study title

SPIRIT2 = Comparison of imatinib versus dasatinib in patients with newly-diagnosed chronic phase chronic myeloid leukaemia [Europe]

Scientific title

A Phase III, Prospective Randomised Comparison of Imatinib 400mg Daily Versus Dasatinib 100mg in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia (EudraCT 2007-006185-15, ClinicalTrials.gov NCT01460693)

Indication and most important inclusion criteria

Patients can be enrolled within 3 months of initial diagnosis of chronic phase CML and cytogenetic confirmation of Philadelphia chromosome or variants of (9;22) translocations. Patients should be non-treated with any TKI (eg imatinib, dasatinib, nilotinib), busulphan, interferon-alpha, homoharringtonine, cytosine arabinoside, or any other investigational agents.

Short description of intervention

Comparison of 5-year event free survival between two treatment arms receiving either dasatinib 100mg or imatinib 400mg. The study aim is to show superiority of the dasatinib arm over the imatinib arm.

Type of study

First line trial

Current status

Recruitment complete - In follow-up

Study sponsor

Newcastle-upon-Tyne NHS Hospitals (Main Sponsor),
Bristol-Myers Squibb (Funder)

Scientific lead / contact

O'Brien, MD, Stephen
Newcastle University Medical School
stephen.o'brien@newcastle.ac.uk

Principal investigator

Stephen O'Brien, MD
SPIRIT Trial Office
International Centre for Life
Newcastle upon Tyne, UK

Additional information

Short protocol in European LeukemiaNet

Study centers / principal investigators

> 150 study centres

Members of trial management committee are based at:

Newcastle upon Tyne, UK
Newcastle University Medical School

Liverpool, UK
Royal Liverpool University Hospital

London, UK
Imperial College London

CA180-357 = Decitabine + Dasatinib for Blast Phase CML

Study title

CA180-357 = Decitabine + Dasatinib for Blast Phase CML [USA]

Scientific title

An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357) [USA]
(Clinicaltrials.gov No. NCT01498445)

Indication and most important inclusion criteria

This study includes patients age 18 years of age or older with chronic myelogenous leukemia in accelerated phase (CML-AP) or in blast phase (CML-BP). Patients may be previously treated or previously untreated.

Short description of intervention

Patients with accelerated or blast phase CML are treated with a combination of decitabine and dasatinib. They will take dasatinib by mouth once a day and they will receive decitabine by vein for up to 10 days in each 28-day cycle.

Type of study

Treatment of advanced disease
In a single country

Current status

Recruiting

Study sponsor

MD Anderson Cancer Center

Scientific lead / contact

Jorge Cortes

Principal investigator

Jorge Cortes

Additional information

Study description in the US register ClinicalTrials.gov, a service of the U. S. National Institutes of Health

Study centers / principal investigators

United States

MD Anderson Cancer Center
University of Texas
Houston, Texas

 

 

ENESTFreedom = Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

Study title

ENESTFreedom = Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients [Asia, Europe, North America, South America]

Scientific title

A Single-arm, Multicenter, Nilotinib Treatment-free Remission Study in Patients With BCR-ABL1 Positive Chronic Myelogenous Leukemia in Chronic Phase Who Have Achieved Durable Minimal Residual Disease (MRD) Status on First Line Nilotinib Treatmen (EudraCT 2012-004092-40, ClinicalTrials.gov NCT01784068)

Indication and most important inclusion criteria

Chronic myeloid leukemia (CML)
Potential participants should have received treatment with nilotinib for at least 12 months and should have had evidence of typical BCR-ABL transcripts (b3a2 and/or b2a2) at the time of CML-CP diagnosis. Eligible patients should be in MR4.5.

Short description of intervention

The main purpose of the study is to investigate whether nilotinib treatment can be safely suspended with no recurrence of CML in selected patients who responded optimally on this treatment.
Nilotinib will be given during the following study phases: consolidation, continuation, prolonged continuation, re-initiation and re-initiation-2 phases.

Type of study

Treatment discontinuation trial

Current status

No longer recruiting. The total duration of the study has been extended to 5 year treatment-free remission (TFR).

Study sponsor

Novartis Pharma AG

Scientific lead / contact

Hans Menssen
hans.menssen@novartis.com
Novartis Oncology

Principal investigator

Hochhaus, Prof. Dr. med. Andreas
Universitätsklinikum Jena
Abteilung Hämatologie und Internistische Onkologie
andreas.hochhaus@med.uni-jena.de

Additional information


Study description in the US register ClinicalTrials.gov,
a service of the U.S. National Institutes of Health

Short protocol in European LeukemiaNet

Study centers

Study centres are participating in the following countries (Further details please access clinicaltrials.gov):

Argentina

Austria

Belgium

Bulgaria

Colombia

Denmark

France

Germany

Greece

Hungary

Ireland

Italy

Japan

Netherlands

Poland

Spain

Sweden

UK

United States

 

 

SIMPLICITY (CA180-330)

Study title

SIMPLICITY (CA180-330) = Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting [Europe, Caribbean, Russian Federation, USA]

Scientific title

Studying Interventions for Managing Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase: The 5-Year Prospective Cohort Study (SIMPLICITY) (ClinicalTrials.gov NCT01244750)

Indication and most important inclusion criteria

Newly-diagnosed chronic phase chronic myeloid leukemia (CP-CML) patients who started their first-line Tyrosine Kinase Inhibitor (TKI) treatment on imatinib, dasatinib or nilotinib in accordance with the timelines below.

To be included in this study. Patients must have been 18 years or older at time of CP-CML diagnosis.

a) Imatinib Groups
Patients who started their first-line Imatinib treatment between January 2, 2008 and September 30, 2010. Patients to whom this applies are defined as retrospective Imatinib patients
− Patients who started their first-line Imatinib treatment on or after October 1, 2010

b) Dasatinib Groups
Patients who started their first-line Dasatinib treatment after the drug was approved in this indication

c) Nilotinib Groups
Patients who started their first-line Nilotinib treatment after the drug was approved in this indication

Patients are also eligible when they have already switched to a subsequent therapy (TKI or other) at the time of enrollment, as long as their first-line and subsequent CML treatment information is available at site.

Short description of intervention

The purpose of this observational study is to better understand the use of tyrosine kinase inhibitors (TKI) in patients newly diagnosed with CML and their quality of life in a real-world setting.

Patients in Group 1 will receive:
Imatinib ≥ 400 mg tablets by mouth once daily or twice daily depending on the dose selected, up to 84 months

Patients in Group 2 will receive:
Dasatinib 100 mg tablet by mouth once daily up to 84 months

Type of study

Other trials

Current status

No longer recruiting

Study sponsor

Bristol-Myers Squibb

Scientific lead / contact

Bristol-Myers Squibb

Principal investigator

See site locations

Additional information

Study description in the US register ClinicalTrials.gov, a service of the U. S. National Institutes of Health

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Study centers / principal investigators

France

Local Institution
Blois cedex, 41016

Local Institution
Bordeaux, 33300

Local Institution
Chalon/Saone cedex, 71100

Local Institution
Chambéry, 73011

Local Institution
Le Mans Cedex 09, 72037

Local Institution
Pierre Benite cedex, 69495

Local Institution
PRINGY cedex, France, 74374

Germany

Local Institution,
Amberg, 92224

Local Institution
Aschaffenburg, 63739

Local Institution
Baden-Baden, 76530

Local Institution
Bamberg, 96049

Local Institution
Berlin, 12203

Local Institution
Berlin, 13353

Local Institution
Bonn, 53105

Local Institution,
Bottrop, 46236

Local Institution
Coburg, 96450

Local Institution
Darmstadt, 64283

Local Institution
Essen, 45136

Local Institution
Frankfurt am Main,

Local Institution
Frankfurt am Main, 60389

Local Institution
Greifswald, 17475

Local Institution
Hamm, 59063

Local Institution,
Hof, 95028

Local Institution
Idar-Oberstein, 55743

Local Institution
Kaiserslautern, 96049

Local Institution
Kassel, 34117

Local Institution
Koblenz, 56068

Local Institution
Köln, 50674

Local Institution
Köln, 50677

Local Institution
Landshut, 84028

Local Institution
Lebach, 66822

Local Institution
Leipzig, 04103

Local Institution
Mühlheim an der Ruhr, 45468

Local Institution
Offenbach, 63065

Local Institution
Potsdam, 14467

Local Institution
Rostock, 18057

Local Institution
Rötha, 04571

Local Institution
Singen, 78224

Local Institution
Soest, 59494

Local Institution
Ulm, 89081Local Institution
Velbert, 42551

Local Institution
Weiden, 92637

Local Institution
Würzburg, 97080

Italy

Local Institution
Bari, 70124

Local Institution
Brescia, 2123

Local Institution
Brindisi, 72100

Local Institution
Catania, 95124

Local Institution
Florence, 50134

Local Institution
Milan, 20122

Local Institution
Milan, 20162

Local Institution
Modena, 44100

Local Institution
Monza, 20052

Local Institution
Pavia, 27100

Local Institution
Perugia, 06156

Local Institution
Pesaro, 61122

Local Institution
Rionero in Vulture, 85028

Local Institution
Roma, 00189

Local Institution
Roma, 00161

Local Institution
Roma, 00168

Local Institution
Siena, 53100

Local Institution
Terni, 05100

Local Institution
Udine, 33100

Netherlands

Local Institution
Hoofddorp, 2134 TM

Puerto Rico

Puerto Rico Hematology Oncology Group
Bayamon, Puerto Rico, 00961

Russian Federation

Local Institution
Saint-Petersburg, 197022

Spain

Local Institution
La Coruña, 15006

Local Institution
Oviedo - Asturias, 33006

Local Institution
Pamplona, 31008

Local Institution
Salamanca, 37007

Local Institution
Santiago de Compostela, 15706

Local Institution
Toledo, 45004

United States

Alabama
Northwest Alabama Cancer Center
Muscle Shoals, Alabama, 35661

Arizona
Arizona Oncology Associates, PC – HAL
Phoenix, Arizona, 85016

Arizona Oncology Associates, PC – NAHOA
Sedona, Arizona, 86336

Arizona Oncology Associates, PC – HOPE
Tucson, Arizona, 85704

Arkansas
Genesis Cancer Center
Hot Springs National Park, Arkansas, 71913

NEA Baptist Clinic
Jonesboro, Arkansas, 72401

Little Rock Hematology Oncology Associates
Little Rock, Arkansas, 72205

California
Pacific Cancer Medical Center Inc
Anaheim, California, 92801

Southwest Cancer Care Medical Group
Escondido, California, 92025

Wilshire Oncology Medical Group, Inc
Glendora, California, 91741

University of Southern California
Los Angeles, California, 90033

St. Joseph's Hospital
Orange, California, 92868

PMK Medical Group, Inc. DBA Ventura
Oxnard, California, 93030

Stockton Hematology Oncology
Stockton, California, 95204

Tahoe Forest Health System Cancer Center
Truckee, California, 96160

Colorado
Rocky Mountain Cancer Centers
Boulder, Colorado, 80303

Connecticut
Medical Oncology and Blood Disorders, LLP
Manchester, Connecticut, 06040

Stamford Hospital
Stamford, Connecticut, 06904

District of Columbia
George Washington University
Washington, District of Columbia, 20237

Washington Hospital Center, Washington Cancer Institute
Washington D.C, District of Columbia, 20010

Florida
Hematology And Medical Oncology Of Southern Palm Beach County
Boynton Beach, Florida, 33435

Broward Oncology Associates
Fort Lauderdale, Florida,33308

Palm Springs Research Institute
Hialeah, Florida, 33012

University of Florida
Jacksonville, Florida, 32209

Baptist Cancer Institute
Jacksonville, Florida, 32207

Watson Clinic
Lakeland, Florida, 33805

Central Florida Health Alliance
Leesburg, Florida, 34748

Baptist Cancer Center
Miami, Florida

Florida Cancer Specialists
New Port Richey, Florida, 34655

Cancer Centers of Florida
Orlando, Florida, 32806

Lake County Oncology and Hematology
Tavares, Florida, 32778

Space Coast Cancer Center
Titusville, Florida, 32796

Georgia
Emory University
Atlanta, Georgia, 30322

Peachtree Hematology-Oncology
Atlanta, Georgia, 30318

Northwest Georgia Oncology Centers, PC
Marietta, Georgia, 30060

Georgia Cancer Specialist
Sandy Springs, Georgia, 30342

Lewis Hall Singeltary Oncology Center
Thomasville, Georgia, 31792

Hawaii
Kaiser Permanente Honolulu
Honolulu, Hawaii, 96819

OnCare
Honolulu, Hawaii, 96813

Straub Clinical & Hospital
Honolulu, Hawaii, 96813

Illinois
Mahafzah Medical Center
Evergreen Park, Illinois, 60805

Delnor Community Hospital
Geneva, Illinois, 60134

Orchard Health Care Research
Niles, Illinois, 60076

Mid-Illinois Hem/Onc Asoc
Normal, Illinois, 61761

North Chicago VA Medical Center
North Chicago, Illinois, 60064

Southern Illinois School of Medicine
Springfield, Illinois, 62794

Carle Cancer Center
Urbana, Illinois, 61801

Central DuPage Hospital
Winfield, Illinois, 60190

Indiana
Saint John's Cancer Center
Anderson, Indiana, 46016

Indiana Blood and Marrow Transplantation
Indianapolis, Indiana, 46237

Investigative Clinical Research of Indiana
Indianapolis, Indiana, 46260

Horizon Oncology Research, Inc
Lafayette, Indiana, 47905

Cancer Care Center, Inc. PC
New Albany, Indiana, 47150

Iowa
N. Iowa Mercy Cancer Center
Mason City, Iowa, 50401

Kansas
Hutchinson Clinic
Hutchinson, Kansas, 67502

Cotton O'Neil Cancer Center
Topeka, Kansas, 66606

Cancer Center of Kansas
Wichita, Kansas, 67214

Kentucky
Central Baptist Hospital
Lexington, Kentucky, 40503

University of Louisville Hospital - Brown Cancer Center
Louisville, Kentucky, 40202

Consultants In Blood Disorders
St Matthews, Kentucky, 40207

Louisiana
Ochsner Clinic Foundation
New Orleans, Louisiana, 70121

Willis-Knighton Cancer System
Shreveport, Louisiana, 71103

Maryland
Maryland Oncology Hematology Pa
Columbia, Maryland, 21044

Frederick Memorial Hospital
Frederick, Maryland, 21701

Massachusetts
Sturdy Hematology & Oncology Associates
Attleboro, Massachusetts, 02703

Boston VA Healthcare System
Boston, Massachusetts, 02130

South Coast Health System
Fall River, Massachusetts, 02720

Commonwealth Hematology-Oncology, P.C.
Quincy, Massachusetts, 02169

UMass Medical Center
Worcester, Massachusetts, 01655

Michigan
Cancer & Hematology Centers of Western Michigan
Grand Rapids, Michigan, 49503

West Michigan Cancer Center
Kalamazoo, Michigan, 49007

Michigan State University
Lansing, Michigan, 48910

Mississippi
North Mississippi Hematology & Oncology
Tupelo, Mississippi, 38801

Missouri
St John's Clinic for Cancer and Hematology
Springfield, Missouri, 65807

Montana
Billings Clinic
Billings, Montana, 59101

Nebraska
Omaha VAMC
Omaha, Nebraska, 68105

New Hamphire
Portsmouth Regional Hospital
Portsmouth, New Hampshire, 03801

New Jersey
Hackensack University Medical Center
Hackensack, New Jersey, 07601

Hematology-Oncology Associates of Northern NJ, PA
Morristown, New Jersey, 07962

Southern Oncology Hematology
Vineland, New Jersey, 08360

New York
Montefiore Medical Center / AECOM
Bronx, New York, 10467

Broome Oncology
Johnson City, New York, 13790

St. Lukes Roosevelt Medical Center
New York, New York, 10019

Advanced Oncology
New York, New York, 10013

Vassar Brothers Medical Center
Poughkeepsie, New York, 12601

Stony Brook University Hospital
Stony Brook, New York, 11794

North Carolina
Alamance Regional Cancer Center
Burlington, North Carolina, 27215

Waverly Hematology Oncology
Cary, North Carolina, 27518

Duke University Medical Center
Durham, North Carolina, 27710

Gaston Hematology Oncology
Gastonia, North Carolina, 28054

East Carolina University
Greenville, North Carolina, 27834

Ohio
Akron General Medical Cente
Akron, Ohio, 44302

Gabrail Cancer Center
Canton, Ohio, 44718

Signal Point Clinical Research Center, LLC
Middletown, Ohio, 45042

Medical Center of Newark
Newark, Ohio, 43055

Oklahoma
Cancer Care Associates
Tulsa, Oklahoma, 74136

Oregon
Oregon Health & Science University
Portland, Oregon, 97239

Hematology/Oncology Salem LLP
Salem, Oregon, 97301

Pennsylvania
Lehigh Valley Hospital
Allentown, Pennsylvania, 18103

St. Luke's Hospital and Health Network
Bethlehem, Pennsylvania, 18015

Medical Oncology Associates of Wyoming Valley, PC
Kingston, Pennsylvania, 18704

Lancaster General Health
Lancaster, Pennsylvania, 17601

Veterans Research Foundation of Pittsburgh
Pittsburgh, Pennsylvania, 15240

Berks Hematology-Oncology
West Reading, Pennsylvania, 19611

Geisinger Health System
Wilkes Barre, Pennsylvania, 18711

Cancer Care Association Of York
York, Pennsylvania, 17403

Rhode Island
Hematology and Oncology Associates of RI
Cranston, Rhode Island, 02920

The Cancer Center at Memorial Hospital
Pawtucket, Rhode Island, 02860

South Carolina
Charleston Cancer Center
Charleston, South Carolina, 29406

South Dakota
Avera Research Institute
Sioux Falls, South Dakota, 57105

Prairie Lakes Healthcare System, Inc
Watertown, South Dakota, 57201

Tennessee
Tennessee Cancer Specialists
Knoxville, Tennessee, 37909

University of Tennessee Medical Center
Knoxville, Tennessee, 37920

Texas
Texas Oncology
Amarillo, Texas, 79106

Texas Oncology - Arlington South
Arlington, Texas, 76014

Texas Oncology-Austin North
Austin, Texas, 78758

Julie & Ben Rogers Cancer Institute
Beaumont, Texas, 77701

Texas Oncology-Dallas Presbyterian Hospital
Dallas, Texas, 75231

Texas Oncology-Medical City Dallas
Dallas, Texas, 75230-2510

Texas Oncology-Methodist Charlton Cancer Center
Dallas, Texas, 75237

MD Anderson Cancer Center
Houston, Texas, 77030

Michael E Debakey Va Medical Center
Houston, Texas, 77030

Texas Oncology
Lewisville, Texas, 75067

Texas Oncology-McAllen South Second
McAllen, Texas, 78503

Texas Oncology
Mesquite, Texas, 75150

Texas Oncology-Midland Allison Cancer Center
Midland, Texas, 79701

Texas Oncology-Odessa West Texas Cancer Center
Odessa, Texas, 79761

Texas Oncology
Paris, Texas, 75460-5004

North Texas Regional Cancer Center
Plano, Texas, 75075

Cancer Care Centers of South Texas
San Antonio, Texas, 78217

Texas Oncology
Waco, Texas, 76712

Virginia
Danville Hematology & Oncology
Danville, Virginia, 24541

Hematology Oncology Associates of Fredricksburg
Fredericksburg, Virginia, 22408

Peninsula Cancer Institute
Newport News, Virginia, 23601

Blue Ridge Cancer Care
Roanoke, Virginia, 4014

Washington
Swedish Cancer Institute-Eastside Hematology/Oncology
Bellevue, Washington, 98005

Providence Cancer Center at Sacred Heart Medical Center
Spokane, Washington, 99208

Wenatchee Valley Medical Center
Wenatchee, Washington, 98801

Yakima Valley Memorial Hospital/North Star Lodge
Yakima, Washington, 98902

West Virginia
Charleston Area Medical Center
Charleston, West Virginia, 25304

City Hospital - West Virginia University Hospital East
Martinsburg, West Virginia, 25401

Wheeling Hospital
Wheeling, West Virginia, 26003

Wisconsin
Aspirus Regional Cancer Center
Wausau, Wisconsin, 53792

 

 

 

Subcategories

Please donate!

Please donate!

LogIn

EU e-Privacy Directive